Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report) today and set a price target of $80.00. The company’s shares opened today at
Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report) today and set a price target of $80.00. The company’s shares opened today at
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of $80.00. The company’s shares closed
In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of $68.00. The company’s shares
Jasper Therapeutics, Inc. ( ($JSPR) ) has released its Q3 earnings. Here is a breakdown of the information Jasper Therapeutics, Inc. presented to its investors. Jasper Therapeutics, Inc. is a
Jasper Therapeutics (JSPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JMP Securities maintained a Buy rating on the